kabutan

Ajinomoto Co., Inc.(2802) Summary

2802
TSE Prime
Ajinomoto Co., Inc.
3,579.0
JPY
+29.0
(+0.82%)
Dec 5, 11:30 am JST
23.07
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
3,577.5
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
28.8
PBR
4.84
Yield
1.34%
Margin Trading Ratio
0.93
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
3,545.0 JPY 22.85 USD
Previous Close Dec 4
3,550.0 JPY 22.84 USD
High Dec 5, 9:46 am
3,588.0 JPY 23.13 USD
Low Dec 5, 9:13 am
3,528.0 JPY 22.73 USD
Volume
1,564,600
Trading Value
5.58B JPY 0.04B USD
VWAP
3563.78 JPY 22.98 USD
Minimum Trading Value
357,900 JPY 2,307 USD
Market Cap
3.60T JPY 0.02T USD
Number of Trades
3,367
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
4,382
1-Year High Nov 10, 2025
20,284
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 117,300 1,964,100 16.74
Nov 21, 2025 96,300 1,771,500 18.40
Nov 14, 2025 144,500 1,764,300 12.21
Nov 7, 2025 294,700 1,762,300 5.98
Oct 31, 2025 247,600 500,800 2.02
Company Profile
Ajinomoto Co., Inc. is a leading comprehensive food company, ranking first in seasonings. The company has diversified into pharmaceuticals, animal feed, and other sectors, and is actively pursuing M&A opportunities.
Sector
Foods
Ajinomoto Co., Inc. is a comprehensive food manufacturer with a primary focus on seasonings, nutritional and processed foods, solution and ingredients, and frozen foods. The company also operates in non-food sectors, including pharmaceutical and food-grade amino acids, biopharmaceutical services (CDMO), and functional materials (such as electronic materials). With numerous subsidiaries both domestically and internationally, Ajinomoto conducts business on a global scale. The company has particularly strong business foundations in Southeast Asia and South America. In the seasoning business, Ajinomoto has local subsidiaries in Thailand, Indonesia, Vietnam, the Philippines, and Malaysia, among others. The frozen food business has also expanded into North America. Additionally, the company is focusing on strengthening its biopharmaceutical services business.